Search the Newsreel

Arrowstreet Capital discloses net short position in DBV Technologies

Arrowstreet Capital has reported a 0.6% net short position in DBV Technologies. This information was generated by Public Technologies (PUBT) using AI, based on original content published by DBV Technologies SA. The article includes disclaimers noting that the content is for informational purposes only …

Claude AI’s Newest Stock Picks Are Also Hedge Fund Favorites: One Breakout Biotech, One AI Chip Bet

Note: the trade details cited in this article come from The Claude Portfolio account on X, a third-party account not affiliated with Anthropic. It tracks how different AI models would trade if given a live portfolio. Claude AI recently added two names that couldn't …

BV Financial Inc (BVFL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for BV Financial Inc (BVFL), detailing future EPS and revenue growth estimates. It includes current stock data, market capitalization, P/E ratio, and highlights peer comparisons with other banking and investment services companies. The financial forecasting section indicates upcoming …

ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ProQR Therapeutics NV (PRQR), indicating a current earnings forecast score of 8.67 and a ranking of 74 out of 387 in its industry. Analysts have set an average price target of $9.50 with a "Buy" rating. The …

BrightView Holdings, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

BrightView Holdings (NYSE: BV) recently reported a surprise Q3 2026 loss, missing analyst revenue estimates and causing its share price to drop 17% in a single day. Despite the miss, analysts are maintaining a positive outlook with an average price target of US$14.80, suggesting …

BrightView Holdings, Inc. Revenue Breakdown – LSX:A2JPBC

This article provides a revenue breakdown for BrightView Holdings, Inc. (LSX:A2JPBC), highlighting its top-performing segment and geographical contribution. Last year, the company generated 2.28 billion EUR in revenue, with the Maintenance Services segment contributing the most at 1.61 billion EUR. The United States was …

DBV Technologies SA (DBV.HM) valuation measures and financial statistics

Projeções de Resultados: AbbVie Inc (ABBV) — LPA e Crescimento de Receita

New Century Logistics (BVI) Ltd (NCEW) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article from TradingKey provides an earnings forecast for New Century Logistics (BVI) Ltd (NCEW), detailing future estimates for EPS and revenue growth. It includes current stock information, market capitalization, P/E ratio, and lists peer companies in the freight and logistics services sector for …

ABVC Biopharma Inc (ABVC) Stock News Today

This article provides the current stock news and financial overview for ABVC Biopharma Inc (ABVC). It highlights the company's stock performance, market capitalization, and various financial and analytical tools available on the TradingKey platform. The article also indicates that more news will be coming …

Dbv Technologies SA (DBVT) Stock News Today

RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has reported a 5.8% beneficial ownership in DBV Technologies S.A. The group collectively owns 18,288,220 ordinary shares, held through 3,657,644 American Depositary Shares (ADSs), with each ADS representing …

ABBV6474383 Bond Price and Chart — FINRA:ABBV6474383

This article provides details about the ABBV6474383 bond issued by AbbVie Inc. It lists key terms such as the coupon rate (5.45%), maturity date (September 15, 2038), and outstanding amount. The article also includes company information for AbbVie, Inc., describing it as a research-based …

BrightView Holdings (NYSE: BV) director adds 50,000 shares through trusts

BrightView Holdings (NYSE: BV) director William L. Cornog purchased 50,000 shares of common stock on August 6, 2026, through trusts for his children and a living trust. These transactions occurred at weighted-average prices of $11.25 and $11.24 per share, contributing to his indirect holdings. …

Analysts’ Top Industrial Goods Picks: BrightView Holdings (BV), BWX Technologies (BWXT)

Analysts have issued neutral ratings for BrightView Holdings (BV) and BWX Technologies (BWXT), indicating neither a bullish nor bearish stance. Goldman Sachs maintained a Hold rating on BrightView with a price target of $10.80, while Maxim Group maintained a Hold rating on BWX Technologies. …

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

This article first appeared on GuruFocus. Cash Position: Ended Q2 2026 with cash, equivalents, and marketable securities of $106 million. Pro Forma Cash: More than $310 million after receiving a $100 million milestone payment from AbbVie and approximately $108 million in net proceeds from …

BrightView Holdings, Inc. Stock 12‑Month Price Target Cut to $16.35, Implies 25% Upside

BrightView Holdings, Inc. (BV) has seen its average 12-month price target reduced from $16.68 to $16.35 by 10 analysts, with individual forecasts ranging from $10 to $24 per share. Despite the cut, this updated target still suggests a potential upside of approximately 25% from …

Oppenheimer Adjusts PT on BrightView Holdings to $16 From $17, Maintains Outperform Rating

Oppenheimer has adjusted its price target for BrightView Holdings (BV) to $16 from the previous $17, while reiterating an Outperform rating on the stock. This update reflects a re-evaluation of the company's financial outlook by the analyst firm. The article also provides a company …

AbbVie Inc. (ABBV) Stock forecasts

Argus Research has raised its target price for AbbVie Inc. (ABBV) to $270, noting the company's status as a research-based biopharmaceutical firm spun off from Abbott Laboratories. AbbVie is a component of the S&P 500, with its shares currently trading at $244.93. The report …

BBVA Argentina names Maria Soledad Duro Ruiz as director after central bank clearance

BBVA Argentina has appointed María Soledad Duro Ruiz to its board as director, with the appointment becoming effective on August 6, 2026. This decision follows clearance from the central bank. The announcement was made by Reuters.

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal subretinal wet AMD studies, …

Enterprise value to EBIT forward of ProQR Therapeutics N.V. – MUN:0PQ

This article provides financial information for ProQR Therapeutics N.V. (MUN:0PQ) focusing on its enterprise value to EBIT forward. It indicates that the market for this stock was closed with no trades. The content primarily lists various financial data points and market analysis tools available …

Morgan Stanley Adjusts PT on BrightView Holdings to $12.50 From $14, Maintains Equalweight Rating

Morgan Stanley has lowered its price target for BrightView Holdings (BV) to $12.50 from $14, while keeping an Equalweight rating on the stock. This adjustment comes after BrightView Holdings reported its Q3 2026 earnings, posting an adjusted EPS of $0.17, which was below FactSet's …

BrightView Holdings, Inc. (NYSE:BV) Receives Average Recommendation of "Hold" from Analysts

BrightView Holdings, Inc. (NYSE:BV) has received an average "Hold" recommendation from analysts, with a consensus 12-month price target of $14.35. The company's fiscal Q3 revenue increased 1.3% year-over-year but missed estimates, and profitability significantly weakened with adjusted EBITDA and net income falling. Management provided …

First Trust Advisors LP Purchases 100,420 Shares of BrightView Holdings, Inc. $BV

First Trust Advisors LP increased its stake in BrightView Holdings, Inc. (NYSE:BV) by 42.7% in the first quarter, acquiring an additional 100,420 shares and bringing its total holdings to 335,460 shares valued at $3,955,000. Other institutional investors also adjusted their positions in BrightView. The …

Pharvaris publishes study on rare angioedema condition

Pharvaris (NASDAQ:PHVS) announced the publication of a qualitative study on acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) in Frontiers in Immunology. This study, the first in-depth assessment of the rare condition, highlighted frequent misdiagnoses, severe attacks, and significant life disruptions for patients who …

AbbVie Inc. $ABBV Position Raised by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in AbbVie Inc. (ABBV) by 8.2% in the second quarter, bringing its total to 68,002 shares valued at $17.1 million. This increase reflects broader institutional confidence, with hedge funds and institutions collectively owning 70.23% of ABBV stock. The …

AbbVie Inc. Stock 12‑Month Price Target Raised to $275.44, Implies 13% Upside

AbbVie Inc.'s stock 12-month average price target has been increased to $275.44 by 25 analysts, up from $274.04. This new target suggests a potential 13% upside based on the Aug. 4 closing price. The consensus rating from 32 analysts remains "Buy," with 24 Buy …

BrightView Q3 Earnings Call Highlights

BrightView Holdings, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:BV) 2026-08-05

BrightView Holdings, Inc. (BV) has published its Q3 2026 earnings call presentation. The company reported an EPS of $0.17, missing estimates by $0.12, and revenue of $717.60 million, missing by $8.88 million, despite a 1.31% year-over-year increase. This article provides access to the slide …

AbbVie Plans to raise $8 billion to finance deal with Apogee Therapeutics

AbbVie Inc. plans to raise $8 billion through investment-grade bonds to fund its $10.9 billion acquisition of Apogee Therapeutics Inc. This strategic move aims to expand AbbVie's portfolio of anti-inflammatory drugs, particularly with Apogee's zumilokibart, a potential competitor to Sanofi's Dupixent. The acquisition reflects …

What AbbVie’s Q2 Earnings Reveal About the Cost of the Apogee Deal

AbbVie's Q2 2026 earnings beat Street estimates across the board, with revenue reaching $16.99 billion and adjusted EPS at $3.65. However, the positive performance was partially offset by a $0.14 dilution from the pending Apogee Therapeutics acquisition, which reduced the full-year guidance upgrade. Despite …

Earnings call transcript: BrightView misses Q3 2026 profit view, shares sink

Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?

BrightView (NYSE:BV) Hits New 12-Month Low After Earnings Miss

BrightView Holdings Releases Q3 2026 Financial Results

BrightView Holdings (NYSE: BV) announced its Q3 2026 financial results, reporting adjusted earnings of $0.17 per share, significantly below the $0.29 consensus estimate. Despite the earnings miss, the company's revenue increased by 1.3% year-over-year to $717.6M, driven mainly by its Maintenance Services segment. BrightView …